TY - JOUR
T1 - Update on front-line therapy for follicular lymphoma
T2 - Chemo-immunotherapy with rituximab and survival
AU - Turturro, Francesco
N1 - Funding Information:
Francesco Turturro has received consultancies and honoraria from Genentech Inc. and Celgene Corp. The author has also recently received a research grant from Merck & Co., Inc.
PY - 2007/7
Y1 - 2007/7
N2 - Over the last three decades, there has been a wide range of options in the management of follicular lymphoma, including observation (watching and waiting), single-agent or combination (e.g., alkylating agents, anthracyclines or purine nucleoside analogs) radiation therapy, immunotherapy alone or in combination with chemotherapy, and interferon. A number of trials studying the treatment of follicular lymphoma patients have investigated the benefit of adding rituximab either concurrently or sequentially to chemotherapy. In the current review, these studies were selected based on the fact that they were randomized Phase III studies with two arms comparing chemotherapy alone with rituximab-based chemo-immunotherapy regimens. In September 2006, the US FDA approved the use of rituximab (Rituxan®) as front-line treatment of patients with follicular lymphoma in combination with cyclophosphamide, vincristine and prednisone (R-CVP) as well as for the treatment of patients with low-grade non-Hodgkin's Lymphoma who achieve stable disease or better following first-line treatment with the same chemotherapy . regimen (CVP →R). The European Medicines Agency also approved the use of rituximab (MabThera®) as front-line treatment of patients with stage III-IV disease in combination with CVP chemotherapy. In conclusion, although the clinical studies discussed in this article provide evidence for a progression-free survival benefit, overall survival advantage was clearly shown for the first time in a recent update of the initial study in patients with follicular lymphoma.
AB - Over the last three decades, there has been a wide range of options in the management of follicular lymphoma, including observation (watching and waiting), single-agent or combination (e.g., alkylating agents, anthracyclines or purine nucleoside analogs) radiation therapy, immunotherapy alone or in combination with chemotherapy, and interferon. A number of trials studying the treatment of follicular lymphoma patients have investigated the benefit of adding rituximab either concurrently or sequentially to chemotherapy. In the current review, these studies were selected based on the fact that they were randomized Phase III studies with two arms comparing chemotherapy alone with rituximab-based chemo-immunotherapy regimens. In September 2006, the US FDA approved the use of rituximab (Rituxan®) as front-line treatment of patients with follicular lymphoma in combination with cyclophosphamide, vincristine and prednisone (R-CVP) as well as for the treatment of patients with low-grade non-Hodgkin's Lymphoma who achieve stable disease or better following first-line treatment with the same chemotherapy . regimen (CVP →R). The European Medicines Agency also approved the use of rituximab (MabThera®) as front-line treatment of patients with stage III-IV disease in combination with CVP chemotherapy. In conclusion, although the clinical studies discussed in this article provide evidence for a progression-free survival benefit, overall survival advantage was clearly shown for the first time in a recent update of the initial study in patients with follicular lymphoma.
KW - B-cell lymphoma
KW - CD20
KW - Follicular lymphoma
KW - Immunotherapy
KW - Low-grade lymphoma
KW - Non-hodgkin's lymphoma
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=34547495536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547495536&partnerID=8YFLogxK
U2 - 10.1586/14737140.7.7.959
DO - 10.1586/14737140.7.7.959
M3 - Review article
C2 - 17627454
AN - SCOPUS:34547495536
SN - 1473-7140
VL - 7
SP - 959
EP - 965
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 7
ER -